A Phase 1, Open-Label Study To Evaluate 5-Ht6 Receptor Occupancy As Measured By Positron Emission Tomography (PET) With Ligand [11c]Pf-04171252 Following Single Oral Dose Administration Of Pf-05212377 (Sam-760) In Healthy Subjects.

Trial Profile

A Phase 1, Open-Label Study To Evaluate 5-Ht6 Receptor Occupancy As Measured By Positron Emission Tomography (PET) With Ligand [11c]Pf-04171252 Following Single Oral Dose Administration Of Pf-05212377 (Sam-760) In Healthy Subjects.

Completed
Phase of Trial: Phase I

Latest Information Update: 07 Jun 2011

At a glance

  • Drugs PF 5212377 (Primary)
  • Indications Alzheimer's disease
  • Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
  • Most Recent Events

    • 07 Jun 2011 Actual end date (May 2011) added as reported by ClinicalTrials.gov.
    • 07 Jun 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 14 Mar 2011 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top